Viracta Therapeutics Inc

NASDAQ:VIRXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Contact Information

Headquarters

2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007

Phone

858-400-8470

Fax

650-266-3501

Executives

Independent Chairman of the Board

Roger Pomerantz

President, Chief Executive Officer, Director

Mark Rothera

Chief Financial Officer

Michael Faerm

Senior Vice President - Finance

Melody Burcar

Chief Medical Officer

Darrel Cohen